Literature DB >> 23494102

Telangiectasis in CREST syndrome and systemic sclerosis: correlation of clinical and pathological features with response to pulsed dye laser treatment.

Shlomit Halachmi1, Osama Gabari, Sarit Cohen, Romelia Koren, Dan Ben Amitai, Moshe Lapidoth.   

Abstract

Telangiectasia are cardinal features of systemic sclerosis (SS) and calcinosis, Raynaud's syndrome, esophageal motility, sclerodactyly, telangiectasias (CREST) syndrome. The etiology of telangiectasia in these syndromes is unknown, but vascular dysfunction has been proposed. However, the telangiectasia of CREST have anecdotally been considered relatively resistant to pulse dye laser (PDL), the treatment of choice for classic telangiectasia. The study was designed to test whether SS/CREST telangiectasia require more treatments than sporadic telangiectasia and to identify clinical and histological features that could explain such an effect. Nineteen skin biopsies from patients with SS or CREST and 10 control biopsies were examined and compared for features that may predict a differential response to PDL. Sixteen cases of SS or CREST treated with PDL between 1997 and 2007 were evaluated and response to treatment was compared with 20 patients with sporadic telangiectasis. Relative to normal skin, CREST/scleroderma telangiectasia exhibited thickened vessels in 17 out of 19 sections and thickened collagen fibers in the reticular or deep dermis in all sections. The number of treatments required to clear SS/CREST telangiectasia was approximately twofold higher. SS/CREST telangiectasia are more resistant to PDL but can be effectively cleared with more treatments.

Entities:  

Mesh:

Year:  2013        PMID: 23494102     DOI: 10.1007/s10103-013-1298-1

Source DB:  PubMed          Journal:  Lasers Med Sci        ISSN: 0268-8921            Impact factor:   3.161


  18 in total

Review 1.  The Th1/Th2 paradigm in the pathogenesis of scleroderma, and its modulation by thalidomide.

Authors:  S J Oliver
Journal:  Curr Rheumatol Rep       Date:  2000-12       Impact factor: 4.592

2.  [Anti-centromere antibody, biological marker of the CREST syndrome as distinct from scleroderma].

Authors:  A M Rouquette-Gally; M H Stern; A C Prost; N Abuaf; J C Homberg; A Combrisson
Journal:  Presse Med       Date:  1985 Jul 13-20       Impact factor: 1.228

3.  Histopathological and ultrastructural features of dermal telangiectasias in systemic sclerosis.

Authors:  Jennifer G Walker; John Stirling; Dimitra Beroukas; Kencana Dharmapatni; David R Haynes; Malcolm D Smith; Michael J Ahern; Peter J Roberts-Thomson
Journal:  Pathology       Date:  2005-06       Impact factor: 5.306

4.  The effect of temperature and other factors on selective microvascular damage caused by pulsed dye laser.

Authors:  B S Paul; R R Anderson; J Jarve; J A Parrish
Journal:  J Invest Dermatol       Date:  1983-10       Impact factor: 8.551

5.  Studies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: direct evidence for a generalized microangiopathy.

Authors:  A J Freemont; J Hoyland; P Fielding; N Hodson; M I Jayson
Journal:  Br J Dermatol       Date:  1992-06       Impact factor: 9.302

6.  Effect of dye laser pulse duration on selective cutaneous vascular injury.

Authors:  J M Garden; O T Tan; R Kerschmann; J Boll; H Furumoto; R R Anderson; J A Parrish
Journal:  J Invest Dermatol       Date:  1986-11       Impact factor: 8.551

7.  Microvasculature can be selectively damaged using dye lasers: a basic theory and experimental evidence in human skin.

Authors:  R R Anderson; J A Parrish
Journal:  Lasers Surg Med       Date:  1981       Impact factor: 4.025

8.  The 'CREST' syndrome. Comparison with systemic sclerosis (scleroderma).

Authors:  E E Velayos; A T Masi; M B Stevens; L E Shulman
Journal:  Arch Intern Med       Date:  1979-11

9.  Tunable pulsed dye laser for the treatment of benign cutaneous vascular ectasia.

Authors:  L L Polla; O T Tan; J M Garden; J A Parrish
Journal:  Dermatologica       Date:  1987

10.  Polarized subsets of human T-helper cells induce distinct patterns of chemokine production by normal and systemic sclerosis dermal fibroblasts.

Authors:  Carlo Chizzolini; Yann Parel; Agneta Scheja; Jean-Michel Dayer
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

View more
  4 in total

1.  Whole-Body Distribution and Clinical Association of Telangiectases in Systemic Sclerosis.

Authors:  Mathieu Jouvray; David Launay; Sylvain Dubucquoi; Vincent Sobanski; Céline Podevin; Marc Lambert; Sandrine Morell-Dubois; Hélène Maillard; Pierre-Yves Hatron; Eric Hachulla; Jonathan Giovannelli
Journal:  JAMA Dermatol       Date:  2018-07-01       Impact factor: 10.282

Review 2.  Patient-reported outcome instruments in clinical trials of systemic sclerosis.

Authors:  John D Pauling; Joana Caetano; Corrado Campochiaro; Giacomo De Luca; Ana Maria Gheorghiu; Maria Grazia Lazzaroni; Dinesh Khanna
Journal:  J Scleroderma Relat Disord       Date:  2019-11-25

Review 3.  Laser treatment of medical skin disease in women.

Authors:  C LaRosa; A Chiaravalloti; S Jinna; W Berger; J Finch
Journal:  Int J Womens Dermatol       Date:  2017-07-21

4.  Palmar telangiectasia is associated with the intensity of smoking.

Authors:  Dragica Petar Pesut; Ana Milan Samardzic; Milica Vojin Bulajic; Tijana Tatjana Cvok-Debeljak
Journal:  J Bras Pneumol       Date:  2019-04-18       Impact factor: 2.624

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.